Samsung Biologics (207940) financial statements

+750.5%since 2018
FY2025 revenue
₩4.6T▲ +30.3%
FY2025 net income
₩1.8T▲ +64.7%
FY2025 free cash flow
₩856.1B▲ +140.7%

Samsung Biologics income statement

Samsung Biologics income statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue4,556,9723,497,1462,938,756
Gross profit2,516,6401,711,1851,490,104
Operating income2,069,2211,321,3661,205,546
Pretax income2,118,6311,384,8691,231,334
Net income1,784,3521,083,316857,691
Diluted earnings per sharen/a15,221.0012,051.00

Samsung Biologics balance sheet

Samsung Biologics balance sheet
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents148,851391,222367,937
Total assets11,060,74217,336,29616,046,197
Total liabilities3,609,6316,431,6206,215,705
Total equity7,451,11110,904,6769,830,492
Long-term debt599,0121,012,757239,783

Samsung Biologics cash flow statement

Samsung Biologics cash flow statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow2,247,8071,659,2551,666,229
Capital expenditure-1,391,741-1,303,573-995,071
Free cash flow (derived)856,067355,682671,158

Quarterly highlights

Quarterly highlights
KRW millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue (derived)1,490,3251,320,9111,257,119308,573
Operating income (derived)640,091586,444580,753378,085
Net income (derived)391,102430,654469,245509,953
Operating cash flow (derived)408,784624,805767,683422,151
Total assets12,670,15112,652,62111,995,00011,060,742

Samsung Biologics major shareholders

Samsung Biologics major shareholders
HolderShare of classSharesFiled
삼성물산74.3%34,402,9536 November 2025
국민연금공단6.9%3,186,12230 July 2026

Samsung Biologics DART filings

Samsung Biologics DART filings
FiledFormType
15 November 2026Quarterly ReportQuarterly report
27 August 2026Major Matters ReportCurrent report
13 August 2026Semiannual ReportHalf-year report
19 July 2026Major Matters ReportCurrent report
14 May 2026Quarterly ReportQuarterly report
11 March 2026Business ReportAnnual report
13 November 2025Quarterly ReportQuarterly report
13 August 2025Semiannual ReportHalf-year report

Common questions

What was Samsung Biologics' revenue in fiscal 2025?

Samsung Biologics reported ₩4.6 trillion in revenue for fiscal 2025, the year ended 31 December 2025, up 30.3% from fiscal 2024.

What was Samsung Biologics' net income in fiscal 2025?

Samsung Biologics reported net income of ₩1.8 trillion for fiscal 2025, the year ended 31 December 2025, up 64.7% from fiscal 2024.

What was Samsung Biologics' free cash flow in fiscal 2025?

Samsung Biologics had ₩856.1 billion in free cash flow in fiscal 2025. Operating cash flow was ₩2.2 trillion and capital expenditure was ₩1.4 trillion.

What were Samsung Biologics' total assets at the end of fiscal 2025?

Samsung Biologics reported total assets of ₩11.1 trillion at the end of fiscal 2025, the year ended 31 December 2025.

How much Samsung Biologics history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.